Adam Olszewski

4 weeks ago | brnw.ch | Adam Olszewski |Michael LeBlanc |Michael Leblanc |Jonathan W. Friedberg

BackgroundFollicular lymphoma (FL) is the second most common non-Hodgkin's lymphoma and currently considered incurable with standard therapies.1 The majority of patients present with advanced disease, and many of them are asymptomatic at diagnosis.

4 weeks ago | ascopubs.org | Adam Olszewski |Michael LeBlanc |Michael Leblanc |Jonathan W. Friedberg

The following protocol information is provided solely to describe how the authors conducted the research underlying this article. The information provided may not reflect the complete protocol or any previous amendments or modifications. As described in the Information for Contributors, JCO OA requests only specific elements of the most recent version of the protocol.

Nov 20, 2023 | targetedonc.com | Adam Olszewski

Adam J. Olszewski, MD, associate professor of medicine at Brown University, lymphoma clinician at Rhode Island Hospital in Providence, Rhode Island, discusses the promising results of a phase 1b/2 study (NCT03677154) of mosunetuzumab (Lunsumio) for the treatment of elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Oct 26, 2023 | targetedonc.com | Adam Olszewski

Adam J. Olszewski, MD, associate professor of medicine at Brown University, lymphoma clinician at Rhode Island Hospital in Providence, Rhode Island, discusses findings from a phase 1b/2 study (NCT03677154) which evaluated treatment with mosunetuzumab (Lunsumio) for the treatment of elderly/unfit patients who were previously untreated for their diffuse large B-cell lymphoma (DLBCL).